Rising Leaders Alles And Fouse Join Celgene Board
This article was originally published in Scrip
Executive Summary
Celgene Corporation has appointed soon-to-be CEO Mark Alles and soon-to-be president and COO Jacqualyn Fouse to its board of directors. Alles has been with Celgene since 2004 and most recently was president and chief operating officer (COO). Celgene has previously announced his promotion to CEO: he will take over from Robert Hugin on March 1, 2016. Prior to being Celgene's president and COO, Alles led the company's hematology and oncology franchise. Currently president of the hematology and oncology franchise, Fouse has been with Celgene since 2010 and was previously Celgene's chief financial officer. Fouse will be promoted to president and COO – effective March 1, 2016.
You may also be interested in...
Text Mining And Machine Reading: The Answer To Pharma's R&D Data Mountain?
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Adherence Issues Add Weight To Digital Trials Push
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
Appointments: Five Prime, Depomed, Gilead, Arix Bioscience and Corbus
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.